Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

How to enhance MSCs therapeutic properties? An insight on potentiation methods

García-Guerrero CA., Fuentes P., Araya MJ., Djouad F., Luz-Crawford P., Vega-Letter AM.

Clinical Trial on Chronic Inflammation, Immune Modulation, published in Stem Cell Res Ther (2024) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Stem Cell Res Ther (2024)
Reported sample size
—
Source database
Europe PMC
PMID
39334487
PMCID
PMC11438163
DOI
10.1186/s13287-024-03935-6
Citations
11

Abstract (original English)

Mesenchymal stem/stromal cells (MSCs) have emerged as a promising tool in the field of regenerative medicine due to their unique therapeutic properties as they can differentiate into multiple cell types and exert paracrine effects. However, despite encouraging results obtained in preclinical studies, clinical trials have not achieved the same levels of efficacy. To improve the therapeutic properties of MSCs, several strategies have been explored. Therefore, in this review, the therapeutic properties of MSCs will be analyzed, and an update and overview of the most prominent approaches used to enhance their therapeutic capabilities will be provided. These approaches include using drugs, molecules, strategies based on biomaterials, and modification parameters in culture. The strategy described shows several common factors among those affected by these strategies that lead to an enhancement of the MSCs therapeutic properties such as the activation of the PI3K/AKT pathway and the increased expression of Heat Shock Proteins and Hypoxia-Inducible Factor. The combined effect of these elements shift MSCs towards a glycolytic state, suggesting this shift is essential for their enhancement.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Mesenchymal Stem CellsAnimalsHumansMesenchymal Stem Cell TransplantationRegenerative MedicineSignal TransductionCell DifferentiationProto-Oncogene Proteins c-aktPhosphatidylinositol 3-Kinases

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research